undamentalytics Newsletter
Sign in

Journey Medical Corp (DERM) stock

Add to watchlist

Add holding +

NASDAQ: DERM Nasdaq Pharmaceuticals Next results ~November 11, 2026

C Fundamentals grade

Journey Medical Corp is a US-listed company in the pharmaceuticals industry. Its financial year ends in December.

Stock price today

Loading chart…

Third-party market data · may be delayed

Model estimate per share

~$9.2

Valuation models combined (3)

Base case. Range ~$3.9–$12. Weighted average of 3 models (growth cash-flow model, forward price-to-earnings vs peers, forward price-to-sales vs peers), the growth cash-flow model counting double.

Price vs value

No Buy/Hold/Sell rating is issued: valued with our growth model, which doesn't carry a Buy/Hold/Sell rating yet.

Journey Medical Corp valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Funds42 adding, 46 cuttingOf 19 active managers that changed their stake, 11 added; quarter to June 30, 2026Fund buyers and sellers

Value diary

Our note on each quarter Journey Medical files

Where Journey Medical stands after its latest 10-Q

Revenue for the twelve months to June 2026 was $68m, up 20.9% on a year earlier, faster than the 15.0% growth a quarter earlier. Free-cash-flow margin rose to 0.3% from -45.5% a year earlier. Operating margin widened to -4.4% from -12.2%. The diluted share count is up 21.6% on a year earlier, which dilutes existing holders. Against its peers on growth, profitability, cash generation and balance sheet, it grades C. It passes 3 of our 6 financial-health checks. Our price-to-sales vs peers value is $1.64 a share, against a share price of $5.37.

Source: 10-Q filed August 12, 2026 on SEC EDGAR · Financials · Valuation

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Next results ~November 11, 2026 (estimated)

Where it stands out: change in growth rate of +5.9pp ranks 11 of 74 pharmaceuticals companies we cover. Where it lags: days sales outstanding of 194 days ranks 54 of 59 pharmaceuticals companies we cover.

Current signal Net income rising while operating cash flow falls: TTM net income grew 30.1% while operating cash flow fell 176.9% — earnings and cash are telling different stories.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Fast growth. Revenue grew 20.9% over the last 12 months, against a median of 10.0% for pharmaceuticals companies we cover.
  • Growth speeding up. The growth rate is 5.9 points higher than a quarter earlier.
  • Margins widening. Operating margin is up 7.8 points on a year ago.

Things to watch

  • Results due soon. Results are expected around 11 November; the share price can move sharply on the day.
  • Loss-making. Operating margin is -4.4%: costs exceed revenue.
  • Share dilution. Diluted shares rose 21.6% in a year.
  • Volatile shares. Over the past year the shares showed annualised volatility of 67% and a beta of 1.7 against the S&P 500.
  • Gross margin slipping. Gross margin is down 2.2 points on a year ago.
  • Below peers: days sales outstanding. Days sales outstanding of 194 days ranks 54 of 59 pharmaceuticals companies we cover (median 72 days).

Latest results: FY2026 Q2

Filed August 12, 2026
Earnings per share
-$0.01 against an average estimate of -$0.02: beat by 55.6%
Revenue
$19m, up 23.3% on a year earlier
Share reaction
+5.2% in the first session after the results on August 12, 2026, against +0.9% for the S&P 500
Next report
November 11, 2026

Journey Medical's figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day-7.4%
  • 1 week-3.6%
  • 1 month-27.5%
  • This year-37.9%
  • 1 year-41.0%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$68.2M
Operating margin
-4.4%
Net margin
-9.0%
EPS (TTM, diluted)
$-0.23

Growth

Revenue growth
+20.9%
Change in growth rate
+5.9 pts
Share count change
+21.6%

Cash

Stock pay % of revenue
8.9%

Earnings

Last results
August 12, 2026
Next results (est.)
November 11, 2026

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Results

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Journey Medical Corp valuation models and calculator

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: valued with our growth model, which doesn't carry a Buy/Hold/Sell rating yet.

Valuation models

We value Journey Medical Corp as an operating company, with every model that fits that kind of business. Cost of equity 8.8%: the 10-year Treasury yield (4.9%) plus a beta of 0.85 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Growth cash-flow model Revenue for this year and next from analysts' consensus, then growth fading to 2.5%; the operating margin moving to profitable peers'; investment needed per dollar of growth from peers; reduced by a failure probability. For young or fast-growing companies. The starting margin is normalized to between -100% and 60%; net margin is a proxy when operating income is not tagged. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$12 ~$7.0–$17 Primary model, counts double
Forward price-to-earnings vs peers Next year's consensus earnings per share times peers' typical (harmonic-mean) forward price-to-earnings. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$3.9 ~$4.1–$8.2 Included
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. — Does not apply: the model gives no positive value
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. — Does not apply: return on equity is not positive
Forward price-to-sales vs peers Next year's consensus sales per share times peers' typical forward price-to-sales; only when earnings are negative. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$6.4 ~$5.7–$16 Included, half weight
Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. — Does not apply: revenue and margins don't support a positive value
Combined value Weighted average of the models that apply: the primary model (growth cash-flow model) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. ~$9.2 ~$3.9–$12 3 models

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Journey Medical Corp with Pharmaceuticals in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Valuation multiples over time Market data may be delayed

At fiscal year end 20212022202320242025Now
Share price$5.38$1.92$5.76$3.91$7.71$4.79
Market value$55m$34m$105m$80m$189m$128m
+ Net debt (− = net cash)−$48m−$1m−$12m$5m$2m$607000
Enterprise value$7m$32m$93m$85m$191m$129m
Multiples
Price / sales 0.9x0.5x1.3x1.4x3.1x1.9x
Price / earnings ——————
Price / free cash flow ——n/m———
EV / EBITDA ——————

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

35 /100

Weak moat

How hard Journey Medical's competitive advantage looks for rivals to wear away, judged from 6 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

  • Returns on capital 0 / 20

    Net income has been a median -10.8% of total assets over 5 years.

  • Pricing power 14 / 20

    Gross margin has been a median 61.3%, moving by 7.8 percentage points (standard deviation) across 5 years.

  • Durability 10 / 20

    Operating margin has been a median -15.6%; its worst year was -59.7%.

AI disruption exposure: Medium. In this industry, AI could change how the product is made or sold, without replacing the core asset. The score above includes a 5-point deduction for that exposure (40 before it).

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Next results: November 11, 2026, after the close. Analysts expect revenue of $20m for the quarter.

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current −$0.13 +73% $78m +25%
Next $0.44 +454% $116m +50%

Next year's EPS estimate has moved −57.3% in 90 days, across 4 analysts.

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is −292.3% on 90 days ago. In the last 30 days, 0 analysts raised Journey Medical Corp's forecast and 0 cut it.

Consensus EPS forecast Journey Medical Corp, last 90 days
−$0.50 $0.00 $0.50 $1.00 $1.50 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: $0.07 Current fiscal year, 60 days ago: −$0.04 Current fiscal year, 30 days ago: −$0.04 Current fiscal year, 7 days ago: −$0.07 Current fiscal year, Now: −$0.13 −$0.13 Next fiscal year, 90 days ago: $1.04 Next fiscal year, 60 days ago: $0.68 Next fiscal year, 30 days ago: $0.68 Next fiscal year, 7 days ago: $0.67 Next fiscal year, Now: $0.44 $0.44

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago $0.07$1.04
60 days ago −$0.04$0.68
30 days ago −$0.04$0.68
7 days ago −$0.07$0.67
Now −$0.13$0.44

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 −$0.02 −$0.01 +55.6%
Mar 2026 −$0.09 −$0.08 +8.6%
Dec 2025 −$0.06 −$0.04 +30.4%
Sept 2025 −$0.04 −$0.09 −140.0%

Adjusted EPS as companies report it, against the average analyst estimate.

Management guidance

Earnings release, August 12, 2026

No numeric guidance in Journey Medical Corp's latest earnings release (filed August 12, 2026). Some companies give their outlook only on the earnings call.

Analyst recommendations

4 analysts, Oct 2026
Buy4100%
Hold00%
Sell00%

Monthly trend

  1. Oct 202644
  2. Sep 202644
  3. Aug 202644
  4. Jul 202644

Counts of recommendations published by analysts covering Journey Medical Corp, by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
18.9%
of tradable shares
Days to cover
14.92
at average volume
Short interest, 1 month
+2%
to October 15, 2026
Held by institutions
48%
of shares
Held by insiders
31.8%
of shares
Employees
58
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

What moved the share price

Last 12 months −41.0%

$8.12 on October 31, 2025 to $4.79

ThenNowEffect
Revenue (last 12 months) $56m $68m +20.9%
P/S multiple 3.2x 1.9x −40.6%
Share count 22m 27m −17.8%

Biggest factor: p/s multiple. Loss-making at one end, so the split uses price/sales.

The effects multiply back to the price change exactly. Results are the last 12 months as known on each date (filings assumed public 45 days after quarter end).

Return and risk by year

Calendar year 20222023202420252026 to date
Return
DERM−64%+200%−32%+97%−38%
Industry peers (median)−49%−14%−2%+7%−12%
S&P 500−18%+26%+25%+18%+11%
Months that ended higher
DERM17%75%50%58%46%
S&P 50042%67%75%75%46%
Largest fall from a high during the year
DERM−80%−59%−49%−22%−53%
S&P 500−25%−10%−8%−19%−9%

Worst fall since November 12, 2021: 90% from November 12, 2021 to May 18, 2023. Getting back needed a 857% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$4.39 – $9.26
From 52-week high
−48.3%
vs 50-day average
−25.8%
vs 200-day average
−27.7%
Volatility (1 year)
67%
Beta vs S&P 500
1.71

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
4 up, 8 down
typical move ±11.8%
After a week
3 up, 9 down
typical move ±10.7%
After a month
5 up, 7 down
typical move ±17.2%
Results releasedNext dayS&P 500 next day5 days21 days
August 12, 2026 +5.2% +0.9% +7.8% +14.4%
May 13, 2026 +26.7% +1.4% +23.2% +26.5%
March 25, 2026 −30.8% −1.2% −32.9% −25.5%
November 12, 2025 −15.0% −1.6% −15.5% −15.2%
August 12, 2025 −7.9% +1.4% −10.2% −6.6%
May 14, 2025 +12.3% +0.6% +7.3% +7.3%
March 26, 2025 −8.6% −1.5% −3.7% +15.3%
February 5, 2025 −6.5% +0.8% −2.4% −3.9%
November 12, 2024 −8.2% −0.3% −4.1% −9.3%
November 4, 2024 −14.4% +1.0% −9.6% −9.4%
August 12, 2024 −3.2% +1.7% −8.2% −3.8%
May 13, 2024 +2.8% +0.5% −3.1% +69.2%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Journey Medical Corp in five measures

Fundamentals grade C
Growth Profitability Cash Balance sheet

Growth, profitability, cash generation and balance sheet are percentiles against the companies we cover in the same industry, from SEC filings (100 = best). Value compares the share price with our modelled value range (50 = at our base value; higher = cheaper). A description of reported data and our model — not a quality score or advice.

Fundamentals

Revenue (TTM) Journey Medical Corp
$50M $60M $70M $80M FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue (TTM), FY23 Q3: $79.9M Revenue (TTM), FY23 Q4: $79.2M Revenue (TTM), FY24 Q1: $80M Revenue (TTM), FY24 Q2: $77.7M Revenue (TTM), FY24 Q3: $57.8M Revenue (TTM), FY24 Q4: $56.1M Revenue (TTM), FY25 Q1: $56.2M Revenue (TTM), FY25 Q2: $56.4M Revenue (TTM), FY25 Q3: $59.4M Revenue (TTM), FY25 Q4: $61.9M Revenue (TTM), FY26 Q1: $64.7M Revenue (TTM), FY26 Q2: $68.2M $68.2M

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue (TTM)
FY23 Q3 $79.9M
FY23 Q4 $79.2M
FY24 Q1 $80M
FY24 Q2 $77.7M
FY24 Q3 $57.8M
FY24 Q4 $56.1M
FY25 Q1 $56.2M
FY25 Q2 $56.4M
FY25 Q3 $59.4M
FY25 Q4 $61.9M
FY26 Q1 $64.7M
FY26 Q2 $68.2M
Revenue growth, TTM YoY Journey Medical Corp
-40% -20% 0% 20% 40% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue growth, TTM YoY, FY23 Q3: 6.2% Revenue growth, TTM YoY, FY23 Q4: 7.5% Revenue growth, TTM YoY, FY24 Q1: 27.8% Revenue growth, TTM YoY, FY24 Q2: 26.4% Revenue growth, TTM YoY, FY24 Q3: -27.7% Revenue growth, TTM YoY, FY24 Q4: -29.1% Revenue growth, TTM YoY, FY25 Q1: -29.7% Revenue growth, TTM YoY, FY25 Q2: -27.4% Revenue growth, TTM YoY, FY25 Q3: 2.8% Revenue growth, TTM YoY, FY25 Q4: 10.2% Revenue growth, TTM YoY, FY26 Q1: 15.0% Revenue growth, TTM YoY, FY26 Q2: 20.9% 20.9%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue growth, TTM YoY
FY23 Q3 6.2%
FY23 Q4 7.5%
FY24 Q1 27.8%
FY24 Q2 26.4%
FY24 Q3 -27.7%
FY24 Q4 -29.1%
FY25 Q1 -29.7%
FY25 Q2 -27.4%
FY25 Q3 2.8%
FY25 Q4 10.2%
FY26 Q1 15.0%
FY26 Q2 20.9%
Operating margin (TTM) Journey Medical Corp
-40% -30% -20% -10% 0% 10% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Operating margin (TTM), FY23 Q3: -12.5% Operating margin (TTM), FY23 Q4: -2.6% Operating margin (TTM), FY24 Q1: -3.3% Operating margin (TTM), FY24 Q2: 2.7% Operating margin (TTM), FY24 Q3: -31.2% Operating margin (TTM), FY24 Q4: -24.4% Operating margin (TTM), FY25 Q1: -12.3% Operating margin (TTM), FY25 Q2: -12.2% Operating margin (TTM), FY25 Q3: -9.3% Operating margin (TTM), FY25 Q4: -13.2% Operating margin (TTM), FY26 Q1: -9.8% Operating margin (TTM), FY26 Q2: -4.4% -4.4%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Operating margin (TTM)
FY23 Q3 -12.5%
FY23 Q4 -2.6%
FY24 Q1 -3.3%
FY24 Q2 2.7%
FY24 Q3 -31.2%
FY24 Q4 -24.4%
FY25 Q1 -12.3%
FY25 Q2 -12.2%
FY25 Q3 -9.3%
FY25 Q4 -13.2%
FY26 Q1 -9.8%
FY26 Q2 -4.4%
FCF margin (TTM) Journey Medical Corp
-60% -40% -20% 0% 20% FY22 Q4 FY23 Q1 FY23 Q2 FY23 Q3 FY23 Q4 FCF margin (TTM), FY22 Q4: -45.5% FCF margin (TTM), FY23 Q1: -32.6% FCF margin (TTM), FY23 Q2: -21.3% FCF margin (TTM), FY23 Q3: 16.2% FCF margin (TTM), FY23 Q4: 0.3% 0.3%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period FCF margin (TTM)
FY22 Q4 -45.5%
FY23 Q1 -32.6%
FY23 Q2 -21.3%
FY23 Q3 16.2%
FY23 Q4 0.3%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-Q. Generated November 3, 2026. Definitions in our methodology.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2020 Dec 2020 2021 Dec 2021 2022 Dec 2022 2023 Dec 2023 2024 Dec 2024 2025 Dec 2025 LTM Jun 2026
Income
Revenue 45 63 74 79 56 62 68
Gross profit 30 31 43 56 35 41 —
EBITDA 8 −35 — — — — —
Operating income 8 −35 −28 −2 −14 −8 −3
Net income 5 −44 −30 −4 −15 −11 −6
Diluted EPS $0.49 −$4.32 −$1.69 −$0.21 −$0.72 −$0.47 −$0.23
Growth (year on year)
Revenue — +41.8% +16.7% +7.5% −29.1% +10.2% +20.9%
EBITDA — −544.0% — — — — —
Operating income — −544.3% — — — — —
Net income — −932.7% — — — — —
Diluted EPS — −981.6% — — — — —
Margins
Gross margin 67.2% 49.2% 58.2% 71.1% 62.8% 66.2% —
EBITDA margin 17.6% −55.2% — — — — —
Operating margin 17.6% −55.2% −37.4% −2.6% −24.4% −13.2% −4.4%
Net margin 11.9% −69.7% −40.2% −4.9% −26.1% −18.5% −9.0%
Free-cash-flow margin — — −45.5% 0.3% −43.0% −20.1% −11.0%
Cash flow
Cash from operations 5 −2 −14 5 −9 −12 −7
Capital spending — — 20 5 15 0 0
Free cash flow — — −34 0 −24 −12 −7
Stock-based pay 0 2 4 3 6 6 6
Free cash flow after stock pay — — −38 −2 −30 −19 −14
Balance sheet
Cash 8 49 32 27 20 24 26
Total debt 0 1 31 16 25 26 26
Net debt (negative = net cash) −8 −48 −1 −12 5 2 1
Diluted shares 11m 10m 18m 18m 20m 24m 27m

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

3 of 6 checks passed · June 30, 2026
What it owns · $98m
Short-term assets $73mLonger-term assets $26m
What it owes, and who funded it · $98m
Short-term liabilities $46mLonger-term liabilities $20mShareholders' equity $32m
  • Short-term assets cover short-term liabilities $73m of assets due within a year against $46m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $73m short-term assets against $20m of longer-dated liabilities.
  • More cash than debt $26m of cash against $25m of debt.
  • Debt below 40% of shareholders' equity Debt is 79% of equity.
  • Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
  • A year's operating cash flow covers at least 20% of debt −$7m of operating cash flow against $25m of debt.
  • Operating profit covers interest at least five times over Operating income of −$3m against $4m of interest.

From Journey Medical Corp's latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

Diluted share count
+21.6%
year over year
R&D spending
0.8%
of revenue
Sales & admin spending
62.9%
of revenue
Days sales outstanding
194 days
receivables vs revenue

Competitors: side by side with peers

Closest by revenue in pharmaceuticals
Last 12 months unless stated DERM RMTI AYTU AQST BFRI ETON Median
Revenue, last 12 months $68m $69m $58m $54m $46m $106m $276m
Revenue growth, last 12 months 20.9% −21.1% −13.3% 22.6% 17.8% 81.5% 9.9%
Revenue growth, 3-year average 3.5% −2.9% −18.8% 5.2% 16.7% 53.8% 5.5%
Revenue growth, latest quarter 23.3% 10.6% 6.4% 38.1% 32.9% 98.6% 6.5%
Gross margin 69.4% 17.7% 64.0% 67.0% — 57.9% 62.0%
Operating margin −4.4% −6.5% −14.4% −97.5% −14.2% 15.4% −5.9%
Operating margin, 3-year average −4.6% −3.8% −9.6% −80.9% −36.6% −2.0% −7.4%
Net margin −9.0% −7.3% −24.8% −144.6% −13.8% 12.0% −7.3%
Cash from operations / revenue −11.0% 4.2% 5.7% −83.9% −17.2% 14.3% 10.2%
Free-cash-flow margin 0.3% 2.2% 5.6% −85.0% −17.2% 14.0% 8.6%
Free-cash-flow margin, 3-year average — — 5.8% −80.3% −31.6% 11.7% 7.4%
Stock pay / revenue 8.9% 2.7% 1.2% 17.3% 2.4% 4.9% 3.6%
Change in share count 21.6% 9.9% 52.9% 27.4% — 29.1% 1.9%

Median of all 75 companies we cover in pharmaceuticals. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Peer comparison

75 pharmaceuticals companies
Measure Company Peer median Rank
Revenue growth Growth 20.9% 10.0% 22 of 74
Change in growth rate Growth +5.9pp -0.3pp 11 of 74
Gross margin Profitability 69.4% 59.8% 20 of 59
Operating margin Profitability -4.4% -5.9% 31 of 67
Net margin Profitability -9.0% -7.3% 40 of 75
Stock pay as % of revenue Cash generation 8.9% 3.6% 53 of 69
Long-term debt as % of assets Balance sheet 20.8% 23.8% 24 of 53
Change in share count Balance sheet 21.6% 1.5% 54 of 62
Days sales outstanding Balance sheet 194 days 72 days 54 of 59

Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).

Where the revenue comes from

Fiscal year to December 31, 2025
Products and services
Line of business Revenue Share YoY
Qbrexza $25M 40.8% ▼ 0.4%
Emrosi $14.7M 24.1% —
Accutane $12.9M 21.0% ▼ 33.6%
Foam Franchise Products Amzeeq Zilxi $5.9M 9.6% ▼ 11.9%
Other Legacy $2.7M 4.5% ▼ 30.9%

From Journey Medical Corp's 10-K filed March 26, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Who owns it

Funds buying and selling
Reported value
$75.5M
Institutions reporting
71
Shares held vs prior quarter
▼ 10.2%
Positions opened / closed
23 / 23

Top buyers and sellers, Q2 2026: 42 institutions bought and 46 sold ; the biggest buyer was Wasatch Advisors LP (+726K shares) and the biggest seller Blackrock, Inc (−872K). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Wasatch Advisors LP $20.2M 2.9M 26.8% ▲ 34.0%
Tang Capital Management LLC $11.4M 1.6M 15.1% 0.0%
Vanguard Capital Management LLC $4.8M 675K 6.3% ▼ 37.6%
Punch & Associates Investment Management, Inc. $3.8M 536K 5.0% New
Pale Fire Capital Se $3.7M 529K 5.0% ▲ 9.7%
Opaleye Management Inc. $2.5M 350K 3.3% ▼ 63.5%
Summit Financial, LLC $2.5M 347K 3.3% ▼ 8.7%
Jane Street Group, LLC $2.3M 320K 3.0% New
Diametric Capital, LP $2.1M 296K 2.8% ▲ 50.5%
Ikarian Capital, LLC $1.8M 251K 2.4% 0.0%
Renaissance Technologies LLC $1.6M 230K 2.2% ▼ 5.3%
Geode Capital Management, LLC $1.5M 216K 2.0% ▼ 53.4%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Journey Medical Corp's complete shareholder register. Values are as reported by the filers .

Insider trading activity

Full insider history and chart
Insider purchases History → $0 0 trades by 0 insiders, last 12 months Insider sales History → $0 0 trades by 0 insiders
Net ▲ $0 net buying

No open-market insider trades reported in the last 12 months.

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

Next expected around November 11, 2026 estimated from the company's past filing pattern, not announced

  • August 12, 2026
  • May 13, 2026
  • March 25, 2026
  • November 12, 2025
  • August 12, 2025
  • May 14, 2025

Recent SEC filings

Data status

When each part of this page on Journey Medical Corp was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Journey Medical Corp in brief

What does Journey Medical Corp do?
Journey Medical Corp is a US-listed company in the pharmaceuticals industry. Its financial year ends in December.
What is Journey Medical Corp's stock ticker?
Journey Medical Corp trades under the ticker DERM on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Journey Medical Corp's revenue, and how fast is it growing?
Over its most recent trailing twelve months, Journey Medical Corp reported revenue of $68.2M, 20.9% higher than a year earlier, according to its SEC filings.
Who are Journey Medical Corp's largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Wasatch Advisors LP, Tang Capital Management LLC and Vanguard Capital Management LLC. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
What is Journey Medical Corp's market cap?
On November 2, 2026, Journey Medical Corp's market capitalisation was about $128M and net debt of $607,000. Market figures come from third-party market data and may be delayed.
How much debt does Journey Medical Corp have?
Journey Medical Corp's debt-to-equity ratio is 79.3%, from its latest balance sheet. The financial health section below sets out its other solvency checks.
Who are Journey Medical Corp's competitors?
In our Pharmaceuticals peer group, the companies closest to Journey Medical Corp are Rockwell Medical, Inc., Aytu Biopharma, Inc, Aquestive Therapeutics, Inc., Biofrontera Inc. and Eton Pharmaceuticals, Inc. The side-by-side comparison below sets their revenue, margins and growth against Journey Medical Corp's.
When is Journey Medical Corp's next earnings date?
Around November 11, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Journey Medical Corp announces its own schedule.